Foresight Diagnostics specializes in advanced liquid biopsy technology for minimal residual disease (MRD) detection. Their flagship product, the Foresight CLARITY MRD platform, is designed to identify early signs of cancer relapse with exceptional sensitivity, capable of detecting one part per million. The company focuses on providing cutting-edge diagnostic tools for oncology, aiming to revolutionize cancer monitoring and treatment strategies.

Foresight Diagnostics collaborates with academic and research institutions, offering access to their platform for investigator-initiated studies. Their technology promises to detect cancer relapse significantly earlier than conventional methods, potentially improving patient outcomes and treatment efficacy. The company's innovative approach positions it at the forefront of liquid biopsy diagnostics, addressing a critical need in cancer care and research.